$234 Million is the total value of Foresite Capital Management IV, LLC's 8 reported holdings in Q4 2022. The portfolio turnover from Q3 2022 to Q4 2022 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| KNTE | Kinnate Biopharma Inc. | $58,997,022 | -49.0% | 9,671,643 | 0.0% | 25.20% | -32.2% | |
| ACRS | Aclaris Therapeutics, Inc. | $44,226,536 | +0.1% | 2,808,034 | 0.0% | 18.89% | +32.9% | |
| PHVS | Pharvaris N.V. | $36,527,918 | +46.7% | 3,246,926 | 0.0% | 15.60% | +94.8% | |
| LYEL | Lyell Immunopharma, Inc. | $34,700,000 | -52.7% | 10,000,000 | 0.0% | 14.82% | -37.1% | |
| KURA | Kura Oncology, Inc. | $22,957,842 | -9.1% | 1,849,947 | 0.0% | 9.81% | +20.7% | |
| SNDX | Buy | Syndax Pharmaceuticals, Inc. | $22,268,750 | +34.3% | 875,000 | +26.8% | 9.51% | +78.4% |
| CBAY | Cymabay Therapeutics, Inc. | $11,205,079 | +79.1% | 1,787,094 | 0.0% | 4.79% | +137.9% | |
| QSI | Quantum-Si Incorporated | $3,241,386 | -33.5% | 1,771,249 | 0.0% | 1.38% | -11.6% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-02-13
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| CymaBay Therapeutics, Inc. | 23 | Q3 2023 | 14.8% |
| Aclaris Therapeutics, Inc. | 18 | Q3 2023 | 18.9% |
| Kura Oncology, Inc. | 16 | Q3 2023 | 11.7% |
| Kinnate Biopharma Inc. | 12 | Q3 2023 | 41.8% |
| Myokardia, Inc. | 12 | Q3 2020 | 17.8% |
| Pharvaris N.V. | 11 | Q3 2023 | 43.4% |
| Cytokinetics Incorporated | 11 | Q2 2021 | 31.6% |
| Lyell Immunopharma, Inc. | 10 | Q3 2023 | 29.2% |
| Insmed Incorporated | 10 | Q1 2020 | 19.2% |
| Biohaven Pharmaceutical Holding Company Ltd. | 9 | Q1 2020 | 14.5% |
View Foresite Capital Management IV, LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2024-04-05 |
| 13F-HR | 2024-02-13 |
| 13F-HR | 2023-11-13 |
| 13F-HR | 2023-08-11 |
| 13F-HR | 2023-05-12 |
| 4 | 2023-05-10 |
| 4 | 2023-02-22 |
| 13F-HR | 2023-02-13 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-12 |
View Foresite Capital Management IV, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.